New hope for rare HIV-2: drug combo shows promise in small trial

This study tested a new first-line treatment for people with HIV-2, a less common form of HIV found mainly in West Africa. Thirty participants who had never taken HIV drugs before received a combination of raltegravir, emtricitabine, and tenofovir. The goal was to see if this combo could control the virus and boost immune cells better than standard treatments. The trial focused on treatment success at 48 weeks, defined by low virus levels and improved immune health.